carboplatin · Avyxa Holdings · NDA 219921
Kyxata
Earliest generic entry, as listed · earliest of 2 marketed strengths
1 Apr 2045
Blocked by patent: US 12427104.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12427104 | drug product · sets the listed date | 1 Apr 2045 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219921 · 001 · RLD · discontinued | solution, intravenous | 20MG/2ML (10MG/ML) | 1 Apr 2045 |
| 219921 · 002 · RLD | solution, intravenous | 80MG/8ML (10MG/ML) | 1 Apr 2045 |
| 219921 · 003 · RLD | solution, intravenous | 500MG/50ML (10MG/ML) | 1 Apr 2045 |